Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.56 |
| ▸ | HTR2B | P41595 | 12/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4995893 | 0.98 | HTR2C (0.55) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL18768218 | 0.88 | RORC (0.46) | HTR2CHTR2B | |
| SCHEMBL5375462 | 0.87 | HTR2C (0.60) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL4034197 | 0.86 | HRH1 (0.54) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5372606 | 0.83 | HTR2C (0.55) | HTR2CHTR2BSLC6A4SLC6A2HTR6 | |
| SCHEMBL171093 | 0.83 | HTR2C (0.47) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14957073 | 0.83 | SLC6A4 (0.57) | HTR2CHTR2BSLC6A4 | |
| SCHEMBL4969392 | 0.83 | HRH1 (0.56) | HTR2CHTR2BSLC6A4 | |
| SCHEMBL5369483 | 0.83 | HTR2C (0.58) | HTR2CHTR2BSLC6A4 | |
| Hydrochloric Acid SCHEMBL10276355 | 0.82 | HTR2C (0.54) | HTR2CHTR2BSLC6A4SLC6A2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478624-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-08 | — | — | EP | disclosed |
| US-7709500-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-100564358-C | The method of a kind of preparation 4-(3, the 4-dichlorophenoxy) piperidines | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | disclosed |
| CN-101268049-A | Novel piperidine derivatives | ASTRAZENECA AB (SE) | 2008-09-17 | — | — | CN | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| CN-100352807-C | substituted piperidine compounds | ASTRAZENECA AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| US-7265227-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-09-04 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| US-20050107428-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| EP-1478624-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| WO-2003068743-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107428-A1 | Chemical compounds | CCR10, CCR3, CXCR5 | HTR2C 572/4885HTR2B 811/4885SLC6A4 2650/4885 |
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR2C 1552/4885HTR2B 1690/4885SLC6A4 3843/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR2C 1552/4885HTR2B 1690/4885SLC6A4 3843/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR2C 1552/4885HTR2B 1690/4885SLC6A4 3843/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR2C 1618/4885HTR2B 1606/4885SLC6A4 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.